Beginning on Wednesday, August 17, Premier Medical Laboratory Services (PMLS), an advanced medical diagnostics lab, will kick off the first of several webinars throughout the month for healthcare providers covering the benefits of AditxtScoreä for COVID-19 immune monitoring. During the webinar, physicians can learn more about the test and how it can quantify their patients’ individual immune profile. The speaker will discuss how the test provides more clarity regarding a patient’s immune response to the virus and/or vaccine and whether this immune response is likely to provide some protection against future infection.
Whether an individual has been vaccinated or experienced a symptomatic or asymptomatic infection with SARS-CoV-2, AditxtScoreä provides timely information on immune status based on each individual’s unique circumstances. Whether, vaccinated, previously infected or both, AditxtScoreä provides a powerful new tool for physicians to use during the current phase of the pandemic[AV1] . Premier Medical Laboratory Services is hosting these webinars, as they believe this is a test that can effectively help manage future surges in COVID-19 cases by taking subjectivity out of the equation when determining next steps on vaccination, boosting, and precautionary measures. AditxtScoreä helps determine who may be vulnerable to COVID-19.
“We hope these webinars will help equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” said Kevin Murdock, CEO of Premier Medical Laboratory Services. “With AditxtScoreä, individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action based on high precision data specific to them.”
AditxtScoreä can be used routinely to track changes in immune response over time and contribute greatly to the continued understanding of responses to SARS-CoV-2. The test may help minimize vaccine hesitancy for those who are not protected by antibodies.
To learn more, physicians and healthcare providers can register for the webinar for the following dates at this link: https://bit.ly/3vmgSX4
- August 17th
- August 31st
- September 14th
AditxtScoreä results provide answers to the following questions:
- Does the individual have antibodies present and, if so, are they robust?
- Are the individual’s antibodies present as a result of vaccination and/or viral infection?
- Is the individual’s immune response likely to provide protection against future infection?
*AditxtScoreä has not been authorized by the FDA to evaluate a person’s level of protection from COVID-19 or future SARS-CoV-2 infection. AditxtScore™ is offered through Premier Medical Laboratory Services as an authorized channel partner. Additional terms, conditions and restrictions may apply. Please click on the following link for further information https://premedinc.com/aditxtscore-immune/
Premier Medical Laboratory Services (PMLS), headquartered in Greenville, South Carolina, is the official health and wellness partner of the Greenville Triumph and an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. PMLS prides itself on delivering some of the most rapid turnaround times of testing results in the industry and patient friendly billing. Their expansive menu of highly advanced tests and screenings include genomic risk assessment assays for various cancers, heart disease, and diabetes, as well as women’s health panels, toxicology, allergy testing, pharmacogenomics, routine blood chemistry, and noninvasive prenatal testing (NIPT). With a heartfelt mission to improve patient care, their in-house research and development team of PhD scientists and forward-thinking laboratory staff are continually innovating ways to provide the most highly advanced medical diagnostics available. For more information about PMLS, please visit www.premedinc.com or call 866.312.4707.
About Aditxt, Inc. (“Aditxt")
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com and www.AditxtScore.com.